PD-1/PD-L1抑制剂免疫治疗对晚期非小细胞肺癌二线及以上患者预后转归的影响

Impact of PD-1/PD-L1 Inhibitor Immunotherapy on Prognostic Regression in Patients with Advanced Non-small Cell Lung Cancer in Second Line and Above

目的探究真实世界中程序性死亡蛋白1(Programmed Death Protein 1,PD-1)/程序性死亡蛋白配体1(Programmed Death Protein Ligand 1,PD-L1)抑制剂治疗对晚期非小细胞肺癌(Non-Small Cell Lung Cancer,NSCLC)二线及以上患者预后转归的影响。方法选取2019年1月—2023年7月涟水县人民医院就诊的112例晚期NSCLC二线及以上患者为研究对象,依据治疗方法分为两组,每组56例,对照组接受二线及以上单药化疗,观察组接受PD-1/PD-L1抑制剂免疫治疗,对比两组生存质量、无进展生存期、总生存期及不良反应发生率。结果化疗4个周期后,观察组生存质量评分显著高于对照组,差异有统计学意义(P<0.05)。观察组无进展生存期、总生存期显著优于对照组,差异有统计学意义(P均<0.05)。观察组不良反应发生率显著低于对照组,且观察组高血压发生人数显著少于对照组,差异有统计学意义(P均<0.05)。结论晚期NSCLC患者二线治疗中PD-1/PD-L1抑制剂免疫治疗能提升患者生存质量,降低其不良反应发生率。

Objective To investigate the effect of real-world programmed death protein 1(PD-1)/programmed death protein ligand 1(PD-L1)inhibitor therapy on the prognostic regression of patients with advanced non-small cell lung cancer(NSCLC)in the second line and above.Methods A total of 112 patients with second-line and above advanced NSCLC treated in Lianshui County People's Hospital from January 2019 to July 2023 were selected as the study objects,and they were divided into two groups according to treatment methods,with 56 cases in each group.The control group received second-line or above single-drug chemotherapy,and the observation group received PD-1/PD-L1 inhibitor immunotherapy.The quality of life,progression-free survival,overall survival and incidence of adverse reactions were compared between the two groups.Results After four cycles of chemotherapy,the quality of life score of observation group was significantly higher than that of control group,and the difference was statistically significant(P<0.05).The progression-free survival and overall survival of the observation group were significantly better than those of the control group,and the differences were statistically significant(both P<0.05).The incidence of adverse reactions in observation group was significantly lower than that in control group,and the number of hypertensive patients in observation group was significantly less than that in control group,and the differences were statistically significant(both P<0.05).Conclusion Immunotherapy with PD-1/PD-L1 inhibitors in the second-line treatment of advanced NSCLC patients can improve the quality of survival and reduce the incidence of adverse reactions.